Home›Trial›NCT06774313
NCT06774313Phase 1ACTIVE NOT RECRUITING

A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants

Study Summary

This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.

Conditions
Healthy Volunteer
Interventions / Drugs
ABBV-142ABBV-142PlaceboPlacebo
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C58/100
Study Details
Enrollment73 participants
Primary Completion—
Lead SponsorAbbVie
Data Retrieved2026-04-11 02:51:51.325669+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 73 participants
Sponsor Catalyst Profile

AbbVie Inc (ABBV) is the sponsoring company for this trial. BiotechSign currently grades this company C (58/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ABBV Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.